Capitalization 956.9Cr 814.13Cr 760.09Cr 713.11Cr 1.32TCr 86TCr 1.44TCr 8.86TCr 3.44TCr 41TCr 3.59TCr 3.51TCr 1,48600Cr P/E ratio 2025 *
46.4x
P/E ratio 2026 * 26.9x
Enterprise value 1.15TCr 980.71Cr 915.61Cr 859.02Cr 1.59TCr 1,04000Cr 1.73TCr 11TCr 4.14TCr 49TCr 4.33TCr 4.23TCr 1,79000Cr EV / Sales 2025 *
2.88x
EV / Sales 2026 * 2.74x
Free-Float
97.96%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
03/12 Charles River Laboratories International, Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 10:00 AM
03/12 Charles River Laboratories International Inc - DSA Net Book-to-Bill Improved Each Month Since Q3 2025 - SEC Filing RE
02/12 Jefferies Adjusts PT on Charles River Laboratories International to $205 From $200, Maintains Buy Rating MT
18/11 Charles River Laboratories International, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 11:30 AM
17/11 Argus Upgrades Charles River Laboratories International to Buy From Hold, Price Target is $200 MT
17/11 Charles River Laboratories International Inc - SEC concludes investigation, no action against Charles River Labs - SEC filing RE
11/11 Morgan Stanley Adjusts Charles River Laboratories International PT to $185 From $170, Maintains Equal Weight Rating MT
10/11 TD Cowen Adjusts Price Target on Charles River Laboratories International to $197 From $205 MT
06/11 The Market Can't Make Up Its Mind Zonebourse
06/11 JPMorgan Adjusts Price Target on Charles River Laboratories International to $165 From $160, Maintains Neutral Rating MT
06/11 Jefferies Adjusts Price Target on Charles River Laboratories International to $200 From $195, Maintains Buy Rating MT
06/11 Barclays Adjusts Price Target on Charles River Laboratories International to $210 From $195, Maintains Overweight Rating MT
06/11 Baird Upgrades Charles River Laboratories International to Outperform From Neutral, Adjusts PT to $199 From $178 MT
More news
1 day-0.22%
1 week+5.29%
Current month+9.14%
1 month+15.07%
3 months+26.85%
6 months+28.76%
Current year+5.33%
More quotes
1 week 182.71
Extreme 182.7143
196.38
1 month 156.72
Extreme 156.72
196.38
Current year 91.86
Extreme 91.8609
199.66
1 year 91.86
Extreme 91.8609
199.66
3 years 91.86
Extreme 91.8609
275
5 years 91.86
Extreme 91.8609
460.21
10 years 65.7
Extreme 65.7
460.21
More quotes
Manager TitleAgeSince
Chief Executive Officer 74 01/01/1992
Director of Finance/CFO 48 29/09/2025
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman 74 01/01/2000
Director/Board Member 68 05/07/2017
Director/Board Member 70 01/10/2019
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.22%+5.29%-1.33%-7.49% 958.96Cr
-2.53%-5.31%+0.19%+14.63% 4.7TCr
+1.37%-0.55%+11.21%+8.37% 3.8TCr
-0.57%-5.04%+71.11%+62.86% 3.57TCr
+0.54%+1.85%+11.96%+17.47% 2.76TCr
+0.96%-1.79%+65.57%+175.14% 1.58TCr
+0.81%+1.06%+66.02%+230.15% 1.51TCr
+2.19%+1.14%-12.05%-2.48% 1.42TCr
-1.61%-1.40%+64.13% - 1.34TCr
+0.65%-3.30%+106.85%+111.04% 1.27TCr
Average +0.23%-0.91%+38.37%+67.74% 2.29TCr
Weighted average by Cap. -0.20%-1.59%+32.16%+52.25%
See all sector performances

Financials

2025 *2026 *
Net sales 400.61Cr 340.84Cr 318.22Cr 298.55Cr 552.03Cr 36TCr 601Cr 3.71TCr 1.44TCr 17TCr 1.5TCr 1.47TCr 62TCr 407.52Cr 346.71Cr 323.7Cr 303.69Cr 561.54Cr 37TCr 611.35Cr 3.77TCr 1.47TCr 17TCr 1.53TCr 1.5TCr 63TCr
Net income 21Cr 18Cr 17Cr 16Cr 30Cr 1.94TCr 32Cr 198.95Cr 77Cr 916Cr 81Cr 79Cr 3.34TCr 38Cr 32Cr 30Cr 28Cr 52Cr 3.44TCr 57Cr 352.55Cr 136.99Cr 1.62TCr 142.95Cr 139.93Cr 5.91TCr
Net Debt 195.79Cr 166.58Cr 155.52Cr 145.91Cr 269.79Cr 18TCr 293.72Cr 1.81TCr 704.04Cr 8.34TCr 734.72Cr 719.15Cr 30TCr 158.92Cr 135.21Cr 126.23Cr 118.43Cr 218.98Cr 14TCr 238.41Cr 1.47TCr 571.46Cr 6.77TCr 596.36Cr 583.72Cr 25TCr
More financial data * Estimated data
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (60.5%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (20.5%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (81.6%) and sales of products (18.4%). Net sales are distributed geographically as follows: the United States (55.3 Europe (26.6%), Canada (11.9%), Asia/Pacific (4.9%) and other (1.3%).
Employees
19,400
More about the company
Date Price Change Volume
11/25/11 194.43 $ -0.22% 6,39,012
10/25/10 194.85 $ +4.76% 11,07,338
09/25/09 185.99 $ -0.60% 10,70,104
08/25/08 187.12 $ +1.52% 8,10,819
05/25/05 184.31 $ +0.15% 7,05,080

Delayed Quote Nyse, December 12, 2025 at 02:30 am IST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
194.43USD
Average target price
189.27USD
Spread / Average Target
-2.66%
Consensus

Quarterly revenue - Rate of surprise